pharmaphorum

JUNE 6, 2022

American entrepreneur and investor Mark Cuban tells us why he and his partners launched the Mark Cuban Cost Plus Drug Company (MCCPDC), a public-benefit corporation and online pharmacy that provides patients access to medications at a lower cost. . US drug prices have soared over the last several decades, causing, at times, financial hardship for patients and their families, so Cuban says he developed MCCPDC with a simple mission – “to be the low-cost provider of medications to patients.”.

Insurance 144

Insurance Labelling Hospitals 144

Outsourcing Pharma

JUNE 6, 2022

Efanesoctocog alfa is an investigational factor III therapy designed to prevent bleeds and bleeding episodes in patients diagnosed with the rare disorder.

81

81

pharmaphorum

JUNE 6, 2022

Eversana’s suite of commercialisation tools for pharma companies will soon have a new component – cognitive behavioural training tools designed to improve the performance of sales representatives. The addition to the company’s portfolio – which already spans services like patient support, digital engagement, dispensing and distribution, and data/analytics – has arrived on the back of an alliance with business and wellness coaching specialist Limitless Minds.

114

114

Outsourcing Pharma

JUNE 6, 2022

Coming back to the real world June 13-16, the industry event will offer face-to-face learning, networking opportunities, and fun, star-studded opportunities.

59

59

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

JUNE 6, 2022

Shares in Praxis Precision Medicines were in freefall today after the company’s efforts to develop a new therapy for major depressive disorder (MDD) ended in failure, forcing a restructuring and staff cuts. The selloff followed the announcement of the phase 2/3 Aria study results with PRAX-114 as a monotherapy for MDD, which showed the GABA positive allosteric modulator was unable to show a significant benefit on any of the study’s primary and secondary endpoints.

111

111

Pharma Times

JUNE 6, 2022

Enhertu reduced the risk of disease progression or death compared to chemotherapy in certain patients with metastatic breast cancer

Chemotherapy 44

Chemotherapy 44

Pharma Times

JUNE 6, 2022

New facility opens on the Cambridge Research Park offering pharmaceutical development services

49

49

pharmaphorum

JUNE 6, 2022

Bristol-Myers Squibb’s all-cash offer for Turning Point Therapeutics – which values the biotech at $4.1 billion – bolsters its position in precision oncology and gives it a lead asset that could challenge cancer medicines from Roche and Pfizer. The $76-per-share offer revolves around repotrectinib (TPX-0005), a tyrosine kinase inhibitor (TKI) targeting ROS1 and NTRK in clinical testing for ROS1-positive, advanced non-small-cell lung cancer (NSCLC) as well as other solid tumours.

Chemotherapy 98

Chemotherapy FDA Labelling 98

pharmaphorum

JUNE 6, 2022

Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a future rivalry if they get regulatory approval. J&J’s Janssen pharma division gave an update on its MajesTEC-1 study of teclistamab , its already-filed BCMAxCD3 bispecific, in RRMM patients who had been treated with at least three prior lines of therapy with a median follow-up of 14 months.

64

64

pharmaphorum

JUNE 6, 2022

Eisai’s first-ever attempt at developing an antibody-drug conjugate for cancer was rewarded with a $3.1 billion licensing deal from Bristol-Myers Squibb, and new data reported at ASCO has given a glimpse into its potential. Farletuzumab ecteribulin – also known as MORAb-202 – is being developed to treat tumours that overexpress folate receptor alpha (FR?

59

59

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA

pharmaphorum

JUNE 6, 2022

In the latest episode of the pharmaphorum podcast, editor in chief Jonah Comstock catches up with Pervaise Khan, Managing Director of Life Sciences, UK and Ireland, Accenture. Jonah and Pervaise take a broad look at pharma’s relationship with its end users – the patients. They discuss the structure of the industry and how it’s changing; the importance of patient trust as well as patient input/engagement; and some practical tips for pharma, especially pharma marketeers, to up their patient centri

40

40

pharmaphorum

JUNE 6, 2022

In March, Gilead Sciences reported that its TROPiCS-02 study of Trodelvy were positive, but the guarded tone of its announcement led to speculation that the data were not as strong as hoped. At ASCO the numbers have been revealed, and the picture isn’t much clearer. The trial evaluated Trodelvy (sacituzumab govitecan) in patients with HR-positive, HER2-negative metastatic breast cancer who received multiple lines of prior treatment, and showed that the drug extended progression-free surviv

Chemotherapy 52

Chemotherapy 52

pharmaphorum

JUNE 6, 2022

With vaccine hesitancy leading to a rise in measles cases, the FDA’s approval of GlaxoSmithKline’s venerable vaccine Priorix for sale in the US looks timely. Priorix was first launched in Europe almost a quarter of a century ago by GSK’s predecessor SmithKline Beecham, and is a combination measles, mumps and rubella (MMR) vaccine now cleared by the FDA for individuals aged 12 months and over.

Vaccines 59

Vaccines FDA 59